Research-only content. This comparison is for educational purposes and does not constitute medical advice. Read full disclaimer →

Selank vs Semax

Last updated: 2026-05-08

Selank is derived from the immunomodulatory peptide tuftsin; Semax is derived from ACTH (adrenocorticotropic hormone).
Selank research focuses on anxiolytic and immune-modulatory effects; Semax research emphasizes cognitive enhancement and neuroprotection.
Both were developed at the Institute of Molecular Genetics in Russia and have regulatory approval there as nasal sprays.
Selank modulates GABA and serotonin systems; Semax primarily influences BDNF and melanocortin pathways.
Both have relatively favorable safety profiles in available studies.

Selank and Semax are both Russian-developed neuropeptides, but Selank is primarily studied for anxiety modulation while Semax is studied for cognitive enhancement and neuroprotection.

Side-by-Side Comparison

Attribute	Selank	Semax
What It Is	A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties.	A synthetic peptide derived from ACTH, studied for cognitive enhancement and neuroprotective effects.
Typical Research Focus
Proposed Mechanisms	Not yet documented	Not yet documented
Evidence Snapshot	Medium Evidenceprescription drug	Medium Evidenceprescription drug
Cautions	Approved in Russia but not FDA-approved in the US Most research published in Russian-language journals Long-term Western clinical data limited	Approved in Russia/Ukraine but not FDA-approved PCAC review scheduled July 24, 2026 for potential 503A Bulks List addition; proposed indications include cerebral ischemia, migraine, and trigeminal neuralgia Western clinical trial data is limited

Selank

What It Is: A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties.
Research Focus
Evidence: Medium Evidence
Cautions: Approved in Russia but not FDA-approved in the US

Most research published in Russian-language journals

Long-term Western clinical data limited

Semax

What It Is: A synthetic peptide derived from ACTH, studied for cognitive enhancement and neuroprotective effects.
Research Focus
Evidence: Medium Evidence
Cautions: Approved in Russia/Ukraine but not FDA-approved

PCAC review scheduled July 24, 2026 for potential 503A Bulks List addition; proposed indications include cerebral ischemia, migraine, and trigeminal neuralgia

Western clinical trial data is limited

When Researchers Compare Them

Selank and Semax are often compared because both originate from the same Russian research institution and are among the few peptides with regulatory approval (in Russia) for neurological applications. Despite this shared background, their mechanisms and primary research applications diverge.

Selank, a synthetic analog of the immunopeptide tuftsin, has been studied for its effects on the GABAergic and serotonergic systems. Research has explored its potential anxiolytic properties and immune-modulatory effects without the sedation typically associated with benzodiazepines.

Semax, derived from a fragment of ACTH (4-10), has been investigated for cognitive enhancement and neuroprotection. Studies suggest it may increase brain-derived neurotrophic factor (BDNF) levels and modulate melanocortin receptors. Research has examined its potential role in stroke recovery, cognitive decline, and attention disorders.

Peptide Profiles

Selank Profile Semax Profile

Citations

[1] Uchakina ON. et al. — Immunomodulatory effects of selank. Bull Exp Biol Med. 2008 Source
[2] Addiction Recovery Peptides 2026 Update — RealPeptides Source